

U. S. Department of Health, Education, and Welfare

FOOD AND DRUG ADMINISTRATION

NOTICES OF JUDGMENT UNDER THE FEDERAL FOOD, DRUG, AND COSMETIC ACT

[Given pursuant to section 705 of the Food, Drug, and Cosmetic Act]

4741-4760

DRUGS AND DEVICES

The cases reported herewith were instituted in the United States district courts by United States attorneys, acting upon reports submitted by the Department of Health, Education, and Welfare. They involve drugs and devices which were adulterated or misbranded within the meaning of the Act when introduced into and while in interstate commerce, or while held for sale after shipment in interstate commerce. These cases involve (1) seizure proceedings which were terminated with the entry of default or consent decrees of condemnation; (2) criminal proceedings which were terminated upon pleas of guilty or nolo contendere; (3) injunction proceedings terminated with the entry of injunctions; and (4) contempt proceedings for violation of an injunction which were terminated upon a plea of guilty. The seizure proceedings are civil actions taken against the *goods* alleged to be in violation, and the criminal, injunction, and contempt proceedings are against the *firms or individuals* charged to be responsible for violations.

Published by direction of the Secretary of Health, Education, and Welfare.

GEO. P. LARRICK, *Commissioner of Food and Drugs.*

WASHINGTON, D. C., August 30, 1956.

CONTENTS*

	Page		Page
Drugs actionable because of potential danger when used according to directions.....	172	Drugs actionable because of failure to bear adequate directions or warning statements.....	183
Drugs requiring certificate or release, for which none had been issued.....	180	Drugs actionable because of deviation from official or own standards.....	187
Drugs in violation of prescription labeling requirements.....	182	Drugs actionable because of false and misleading claims.....	188

*For violative sales of prescription drugs, see No. 4742; presence of a habit-forming narcotic without warning statement, Nos. 4747-4759; omission of, or unsatisfactory, ingredients statements, Nos. 4743, 4745; sale under name of another drug, No. 4755; failure to bear a label containing an accurate statement of the quantity of the contents, Nos. 4745, 4747-4749; failure to bear a label containing the name and place of business of the manufacturer, packer, or distributor, Nos. 4744, 4745.